Hanhsing Wu, MD
Hematology/Oncology · San Carlos
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 14
- 2 carriers
- Office
- 1
Offices
1 location · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: El Camino Health · Santa Monica - UCLA Med Ctr & Orthopaedic Hospital. That is not proof they admit you there this week.
Plans that list them
14 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Wu’s office at (415) 600-1000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
14 of 14 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A63128 · Current
Licensed to practise in California · since 1997 · expires 2026-10-31 · Yale University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Santa Monica - UCLA Med Ctr & Orthopaedic HospitalSanta Monica, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsPatients rate it 3 of 5 · 75% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Pressure ulcer rate: 0.09 (0 to 0.59) · 6,805 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.667, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.6 to 1) · 1,274 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Santa Monica - UCLA Med Ctr & Orthopaedic Hospital
Behind the star rating — Deaths: 3 better, 4 the same, 0 worse of 7 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 1 better, 7 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Pressure ulcer rateComplications and deaths | 0.09 (0 to 0.59) · 6,805 cases | Better | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.667 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1) · 1,274 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.87 (0 to 1.75) · 1,532 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.03 (0.76 to 1.31) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.96 (97.85 to 194.07) · 118 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 87 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.4 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.1 · 295 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 9.4 · 497 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.7 · 100 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.8 · 2,432 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.39) · 7,694 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.07 to 0.44) · 8,081 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.95 (3.16 to 6.74) · 1,949 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.82 (0.22 to 3.41) · 915 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.63 (0.18 to 3.08) · 1,832 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.05 (4.53 to 17.57) · 886 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 8.16 (5.05 to 11.26) · 893 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.62 (0.15 to 3.09) · 396 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 336 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.902 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.479 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.612 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.274 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.5 · 99 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.5 · 449 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 57.2 · 67 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 386 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 41.3 · 584 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.7 · 605 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.7 (3.1 to 7.3) · 81 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.5 (7.5 to 14.8) · 81 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.6 · 304 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.4 · 105 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.2 (9.5 to 15.5) · 1,955 cases | No different | Jan 2022 – Dec 2024 |
What patients said (639 patients answered, 19% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 73% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 56% |
| "YES", patients would definitely recommend the hospital | 75% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$4,896,468
Medicare paid this office $4,896,468 for 864 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, pembrolizumab, 1 mg | 29 | $697,371 | None |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 13 | $394,558 | None |
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 21 | $300,941 | None |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 17 | $221,060 | None |
| Injection, vedolizumab, intravenous, 1 mg | 12 | $179,740 | None |
See all 53 services
| Injection, pembrolizumab, 1 mg | 29 | $697,371 | None |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 13 | $394,558 | None |
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 21 | $300,941 | None |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 17 | $221,060 | None |
| Injection, vedolizumab, intravenous, 1 mg | 12 | $179,740 | None |
| Injection, tocilizumab, 1 mg | 12 | $82,433 | None |
| Long return visit (40+ min) | 169 | $75,964 | $165 |
| Administration of chemotherapy into vein, 1 hour or less | 171 | $71,504 | $141 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 30 | $66,021 | $16 |
| Injection, golimumab, 1 mg, for intravenous use | 14 | $63,351 | None |
| Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | 15 | $61,173 | $21 |
| Injection, infliximab, excludes biosimilar, 10 mg | 17 | $59,387 | None |
| Injection, denosumab, 1 mg | 25 | $42,457 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 183 | $39,302 | $67 |
| Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | 14 | $37,097 | $114 |
| Return visit (30+ min) | 186 | $29,980 | $111 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 22 | $23,262 | None |
| Administration of additional new drug or substance into vein, 1 hour or less | 67 | $14,446 | $69 |
| Administration of chemotherapy into vein, each additional hour | 76 | $8,251 | $29 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 17 | $7,793 | $78 |
| Injection of additional new drug or substance into vein | 115 | $7,343 | $16 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 41 | $6,307 | $21 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 255 | $5,437 | $15 |
| Administration of additional new drug or substance into vein using push technique | 29 | $5,335 | $59 |
| New patient visit (45+ min) | 33 | $5,230 | $158 |
| Bcg live intravesical instillation, 1 mg | 14 | $5,151 | None |
| Short return visit (20+ min) | 57 | $4,898 | $78 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 59 | $4,613 | $30 |
| Instillation of anti-cancer drug into bladder | 16 | $4,555 | $84 |
| Injection, cyclophosphamide, not otherwise specified, 5 mg | 12 | $4,492 | None |
| Injection of drug or substance into vein | 89 | $3,949 | $36 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $3,827 | $106 |
| Injection, zoledronic acid, 1 mg | 135 | $3,324 | None |
| New patient visit (30+ min) | 27 | $2,800 | $104 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 27 | $2,577 | $37 |
| Injection, carboplatin, 50 mg | 32 | $2,226 | None |
| Injection, leucovorin calcium, per 50 mg | 14 | $1,940 | None |
| Injection of drug or substance under skin or into muscle | 70 | $1,901 | $14 |
| Injection, fosaprepitant, 1 mg | 45 | $1,877 | None |
| Irrigation of implanted venous access drug delivery device | 30 | $1,682 | $25 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 36 | $1,484 | $20 |
| Injection, paclitaxel, 1 mg | 23 | $1,421 | None |
| Infusion into a vein for hydration, 31-60 minutes | 13 | $1,212 | $35 |
| Injection, fluorouracil, 500 mg | 14 | $623 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 17 | $515 | $25 |
| Infusion into a vein for hydration, each additional hour | 16 | $463 | $13 |
| Infusion, normal saline solution, 250 cc | 264 | $298 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 73 | $201 | None |
| Injection, methylprednisolone sodium succinate, 5 mg | 19 | $182 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 69 | $153 | None |
| Infusion, normal saline solution , 1000 cc | 14 | $111 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 66 | $105 | None |
| Unclassified drugs | 27 | $33 | None |
Who their Medicare patients are
864 Original Medicare patients in 2024. Average age 77 · Under 65 2% · 85 and older 15% · Women 72% · Also on Medicaid 10% · Health risk score 1.36. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 64% · Cancer 49% · Chronic kidney disease 24% · Diabetes 23% · Coronary heart disease 19% · Depression 18% · Atrial fibrillation 15% · Heart failure 11% · COPD 11% · Dementia 5% · Stroke 5%.
The office billed $16,480,280, Medicare allowed $6,159,354 and paid $4,896,468; for 229,898 services of 154 kinds; $4,572,366 of it was for drugs given in the office and $324,102 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 864 | 229,898 | 77 | 1.36 | $16,480,280 | $4,896,468 |
| 2023 | 753 | 191,040 | 76 | 1.37 | $12,758,341 | $3,660,383 |
| 2022 | 759 | 190,378 | 76 | 1.38 | $11,561,797 | $3,480,263 |
| 2021 | 750 | 211,362 | 76 | 1.44 | $12,617,378 | $4,091,960 |
| 2020 | 632 | 120,848 | 76 | 1.62 | $7,138,659 | $2,167,207 |
| 2019 | 746 | 162,048 | 76 | 1.71 | $8,795,872 | $2,759,677 |
| 2018 | 551 | 72,382 | 75 | 1.67 | $4,286,212 | $1,362,912 |
| 2017 | 619 | 78,528 | 75 | 1.67 | $4,614,410 | $1,357,890 |
| 2016 | 522 | 51,748 | 75 | 1.66 | $2,925,601 | $799,730 |
| 2015 | 548 | 63,242 | 75 | 1.66 | $3,263,713 | $895,845 |
| 2014 | 413 | 54,348 | 75 | 1.53 | $3,065,806 | $794,604 |
| 2013 | 368 | 27,210 | 75 | 1.67 | $2,079,252 | $490,042 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 48 services
| Injection, pembrolizumab, 1 mg | 23 | $682,249 | None |
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 20 | $309,087 | None |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 13 | $160,921 | None |
| Long return visit (40+ min) | 164 | $77,088 | $164 |
| Administration of chemotherapy into vein, 1 hour or less | 133 | $66,831 | $145 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 19 | $63,833 | $22 |
| Injection, infliximab, excludes biosimilar, 10 mg | 18 | $60,964 | None |
| Injection, tocilizumab, 1 mg | 11 | $55,037 | None |
| Injection, denosumab, 1 mg | 23 | $46,324 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 177 | $39,386 | $69 |
| Return visit (30+ min) | 173 | $27,744 | $116 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 22 | $18,443 | None |
| Administration of additional new drug or substance into vein, 1 hour or less | 49 | $11,563 | $70 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 41 | $6,429 | $22 |
| New patient visit (45+ min) | 39 | $6,265 | $161 |
| Administration of chemotherapy into vein, each additional hour | 62 | $5,856 | $30 |
| Injection of additional new drug or substance into vein | 81 | $5,277 | $16 |
| Short return visit (20+ min) | 57 | $5,181 | $80 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 52 | $5,170 | $31 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $5,156 | $110 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 12 | $4,137 | $0 |
| Administration of additional new drug or substance into vein using push technique | 22 | $3,747 | $60 |
| Injection, zoledronic acid, 1 mg | 116 | $3,727 | None |
| Injection of drug or substance into vein | 63 | $3,074 | $38 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $2,918 | $73 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 29 | $2,594 | $37 |
| Instillation of anti-cancer drug into bladder | 13 | $2,521 | $84 |
| Bcg live intravesical instillation, 1 mg | 11 | $2,468 | None |
| Injection of drug or substance under skin or into muscle | 55 | $2,331 | $14 |
| New patient visit (30+ min) | 22 | $2,299 | $104 |
| Drawing of blood for a medical problem | 12 | $2,161 | $94 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 29 | $1,504 | $21 |
| Telephone medical discussion with physician, 21-30 minutes | 12 | $1,471 | $113 |
| Injection, fosaprepitant, 1 mg | 28 | $1,337 | None |
| Infusion into a vein for hydration, 31-60 minutes | 12 | $1,312 | $35 |
| Injection, paclitaxel, 1 mg | 19 | $1,196 | None |
| Injection, carboplatin, 50 mg | 28 | $1,056 | None |
| Infusion into a vein for hydration, each additional hour | 38 | $879 | $13 |
| Irrigation of implanted venous access drug delivery device | 18 | $827 | $27 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 12 | $813 | $45 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 15 | $370 | $25 |
| Infusion, normal saline solution, 250 cc | 232 | $268 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 59 | $191 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 63 | $146 | None |
| Infusion, normal saline solution , 1000 cc | 13 | $125 | None |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 16 | $88 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 40 | $84 | None |
| Unclassified drugs | 18 | $17 | None |
2022: 43 services
| Injection, pembrolizumab, 1 mg | 25 | $726,516 | None |
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 22 | $306,225 | None |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 15 | $166,529 | None |
| Long return visit (40+ min) | 126 | $75,712 | $164 |
| Administration of chemotherapy into vein, 1 hour or less | 147 | $67,726 | $151 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 16 | $63,837 | $37 |
| Injection, infliximab, excludes biosimilar, 10 mg | 21 | $61,171 | None |
| Injection, golimumab, 1 mg, for intravenous use | 13 | $57,860 | None |
| Injection, denosumab, 1 mg | 20 | $33,149 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 135 | $31,127 | $73 |
| Return visit (30+ min) | 158 | $25,565 | $112 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 27 | $19,561 | None |
| Administration of additional new drug or substance into vein, 1 hour or less | 45 | $11,579 | $73 |
| Short return visit (20+ min) | 79 | $7,521 | $79 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 68 | $7,000 | $32 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 16 | $6,971 | $1 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 31 | $6,133 | $22 |
| Injection of additional new drug or substance into vein | 92 | $5,956 | $17 |
| Administration of chemotherapy into vein, each additional hour | 64 | $4,834 | $31 |
| Bcg live intravesical instillation, 1 mg | 15 | $4,600 | None |
| Instillation of anti-cancer drug into bladder | 16 | $4,307 | $88 |
| Injection of drug or substance under skin or into muscle | 59 | $3,714 | $14 |
| Administration of additional new drug or substance into vein using push technique | 19 | $3,628 | $63 |
| Injection of drug or substance into vein | 76 | $3,488 | $39 |
| New patient visit (45+ min) | 22 | $3,221 | $146 |
| New patient visit (30+ min) | 27 | $2,933 | $109 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 33 | $2,665 | $36 |
| Injection, zoledronic acid, 1 mg | 89 | $2,507 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $1,833 | $65 |
| Telephone medical discussion with physician, 21-30 minutes | 12 | $1,749 | $109 |
| Injection, fosaprepitant, 1 mg | 31 | $1,515 | None |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 12 | $1,506 | None |
| Injection, carboplatin, 50 mg | 30 | $1,418 | None |
| Injection, paclitaxel, 1 mg | 22 | $1,299 | None |
| Irrigation of implanted venous access drug delivery device | 18 | $1,089 | $29 |
| Telephone medical discussion with physician, 11-20 minutes | 13 | $990 | $71 |
| Collection of blood sample from implanted device | 13 | $419 | $26 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 12 | $319 | $25 |
| Injection, dexamethasone sodium phosphate, 1 mg | 67 | $201 | None |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 17 | $127 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 64 | $119 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 42 | $82 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 11 | $24 | None |
2021: 47 services
| Injection, pembrolizumab, 1 mg | 19 | $736,664 | None |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 18 | $213,466 | None |
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 18 | $210,035 | None |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 13 | $116,919 | $51 |
| Injection, infliximab, excludes biosimilar, 10 mg | 20 | $101,159 | None |
| Injection, denosumab, 1 mg | 34 | $100,625 | None |
| Administration of chemotherapy into vein, 1 hour or less | 153 | $84,308 | $161 |
| Injection, golimumab, 1 mg, for intravenous use | 15 | $75,702 | None |
| Long return visit (40+ min) | 147 | $52,974 | $167 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 11 | $45,357 | None |
| Return visit (30+ min) | 173 | $32,560 | $115 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 126 | $30,075 | $79 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 37 | $27,890 | None |
| Short return visit (20+ min) | 130 | $13,688 | $76 |
| Administration of additional new drug or substance into vein, 1 hour or less | 51 | $12,421 | $78 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 68 | $8,324 | $34 |
| Injection of additional new drug or substance into vein | 106 | $8,213 | $18 |
| Administration of chemotherapy into vein, each additional hour | 64 | $7,561 | $33 |
| Administration of additional new drug or substance into vein using push technique | 21 | $5,075 | $67 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 30 | $4,952 | $23 |
| Bcg live intravesical instillation, 1 mg | 12 | $4,766 | None |
| Instillation of anti-cancer drug into bladder | 14 | $4,260 | $85 |
| New patient visit (45+ min) | 26 | $4,232 | $163 |
| Injection of drug or substance into vein | 85 | $4,121 | $43 |
| Injection of drug or substance under skin or into muscle | 75 | $4,047 | $14 |
| Injection, fosaprepitant, 1 mg | 36 | $3,738 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $3,654 | $66 |
| Injection, zoledronic acid, 1 mg | 91 | $3,588 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 45 | $3,501 | $35 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $2,866 | $96 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 19 | $2,345 | None |
| New patient visit (30+ min) | 22 | $2,314 | $105 |
| Injection, paclitaxel, 1 mg | 25 | $1,974 | None |
| Irrigation of implanted venous access drug delivery device | 21 | $1,671 | $32 |
| Injection, carboplatin, 50 mg | 32 | $1,565 | None |
| Telephone medical discussion with physician, 21-30 minutes | 12 | $1,169 | $90 |
| Short return visit | 21 | $1,106 | $53 |
| Collection of blood sample from implanted device | 15 | $894 | $28 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 23 | $697 | $22 |
| Infusion into a vein for hydration, 31-60 minutes | 11 | $619 | $39 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 14 | $312 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 73 | $251 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 72 | $172 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 49 | $105 | None |
| Infusion, normal saline solution , 1000 cc | 12 | $53 | None |
| Infusion, normal saline solution, 250 cc | 23 | $13 | None |
| Unclassified drugs | 11 | $8 | None |
2020: 44 services
| Injection, pembrolizumab, 1 mg | 12 | $161,352 | None |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 14 | $158,631 | None |
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 17 | $148,995 | None |
| Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | 12 | $108,771 | $50 |
| Injection, infliximab, excludes biosimilar, 10 mg | 19 | $81,800 | None |
| Injection, denosumab, 1 mg | 21 | $55,970 | None |
| Injection, tocilizumab, 1 mg | 12 | $52,874 | None |
| Injection, golimumab, 1 mg, for intravenous use | 11 | $51,925 | None |
| Return visit (30+ min) | 217 | $49,508 | $97 |
| Administration of chemotherapy into vein, 1 hour or less | 113 | $44,039 | $152 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 34 | $27,538 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 92 | $19,788 | $75 |
| Injection, fosaprepitant, 1 mg | 28 | $8,704 | None |
| Administration of additional new drug or substance into vein, 1 hour or less | 42 | $6,686 | $73 |
| Short return visit (20+ min) | 66 | $6,361 | $71 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $6,244 | $98 |
| Injection of additional new drug or substance into vein | 77 | $4,795 | $17 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 53 | $4,764 | $33 |
| New patient visit (45+ min) | 27 | $4,297 | $159 |
| Administration of chemotherapy into vein, each additional hour | 43 | $4,226 | $32 |
| Telephone medical discussion with physician, 21-30 minutes | 25 | $3,487 | $97 |
| Long return visit (40+ min) | 21 | $3,447 | $144 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 32 | $3,203 | $22 |
| Administration of additional new drug or substance into vein using push technique | 20 | $3,170 | $63 |
| Telephone medical discussion with physician, 11-20 minutes | 34 | $2,896 | $71 |
| Injection, zoledronic acid, 1 mg | 61 | $2,483 | None |
| Injection of drug or substance into vein | 59 | $2,409 | $37 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 40 | $2,361 | $33 |
| Injection of drug or substance under skin or into muscle | 52 | $2,135 | $14 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $1,821 | $67 |
| Irrigation of implanted venous access drug delivery device | 22 | $1,345 | $28 |
| Injection, carboplatin, 50 mg | 25 | $933 | None |
| Influenza vaccine split virus, preservative free | 15 | $915 | $61 |
| Injection, paclitaxel, 1 mg | 16 | $848 | None |
| Red blood cells, leukocytes reduced, each unit | 11 | $756 | $36 |
| Transfusion of blood or blood products | 13 | $661 | $37 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 19 | $533 | $24 |
| Administration of influenza virus vaccine | 15 | $314 | $21 |
| Injection, dexamethasone sodium phosphate, 1 mg | 57 | $130 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 57 | $114 | None |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 11 | $72 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 38 | $51 | None |
| Infusion, normal saline solution , 1000 cc | 12 | $29 | None |
| Infusion, normal saline solution, 250 cc | 21 | $11 | None |
2019: 46 services
| Injection, rituximab, 10 mg | 23 | $225,420 | None |
| Injection, pembrolizumab, 1 mg | 12 | $193,294 | None |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 14 | $182,891 | None |
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 21 | $157,416 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 24 | $117,418 | None |
| Return visit (30+ min) | 287 | $67,944 | $97 |
| Injection, tocilizumab, 1 mg | 11 | $59,977 | None |
| Injection, denosumab, 1 mg | 24 | $59,648 | None |
| Administration of chemotherapy into vein, 1 hour or less | 151 | $58,208 | $149 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 13 | $52,549 | None |
| Leuprolide acetate (for depot suspension), 7.5 mg | 37 | $33,659 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 107 | $24,694 | $76 |
| Injection, fosaprepitant, 1 mg | 24 | $13,212 | None |
| Administration of additional new drug or substance into vein, 1 hour or less | 56 | $9,657 | $72 |
| Injection of additional new drug or substance into vein | 105 | $7,786 | $17 |
| Administration of chemotherapy into vein, each additional hour | 71 | $7,744 | $31 |
| New patient visit (45+ min) | 41 | $6,234 | $152 |
| Administration of prolonged chemotherapy into vein | 12 | $5,759 | $152 |
| Administration of additional new drug or substance into vein using push technique | 27 | $5,016 | $62 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $4,467 | $84 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $4,262 | $95 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 55 | $4,095 | $32 |
| Injection of drug or substance into vein | 81 | $4,000 | $40 |
| Injection, zoledronic acid, 1 mg | 83 | $3,755 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 28 | $3,624 | $22 |
| Short return visit (20+ min) | 41 | $3,410 | $67 |
| Injection of drug or substance under skin or into muscle | 66 | $3,177 | $17 |
| Irrigation of implanted venous access drug delivery device | 40 | $3,148 | $29 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 43 | $2,894 | $32 |
| Long return visit (40+ min) | 16 | $2,679 | $134 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $2,320 | $66 |
| Injection, paclitaxel, 1 mg | 29 | $1,717 | None |
| Injection, carboplatin, 50 mg | 32 | $1,458 | None |
| Injection, leucovorin calcium, per 50 mg | 11 | $1,448 | None |
| New patient visit (30+ min) | 13 | $1,351 | $104 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 11 | $1,094 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 12 | $898 | $21 |
| Injection, fluorouracil, 500 mg | 13 | $548 | None |
| Collection of blood sample from implanted device | 13 | $506 | $27 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 18 | $442 | $22 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 15 | $313 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 69 | $195 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 65 | $168 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 61 | $96 | None |
| Infusion, normal saline solution, 250 cc | 50 | $32 | None |
| Injection, furosemide, up to 20 mg | 11 | $11 | None |
2018: 29 services
| Injection, pembrolizumab, 1 mg | 13 | $260,252 | None |
| Return visit (30+ min) | 249 | $54,988 | $94 |
| Injection, denosumab, 1 mg | 13 | $30,802 | None |
| Administration of chemotherapy into vein, 1 hour or less | 74 | $23,888 | $149 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 18 | $12,112 | None |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 19 | $8,713 | $84 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 32 | $7,302 | $94 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 64 | $6,995 | $76 |
| New patient visit (45+ min) | 37 | $5,665 | $153 |
| Short return visit (20+ min) | 68 | $4,791 | $61 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 29 | $4,184 | $65 |
| Long return visit (40+ min) | 25 | $3,405 | $131 |
| Administration of additional new drug or substance into vein, 1 hour or less | 26 | $3,340 | $71 |
| Injection of additional new drug or substance into vein | 56 | $2,860 | $18 |
| Administration of chemotherapy into vein, each additional hour | 26 | $2,119 | $32 |
| Injection of drug or substance under skin or into muscle | 43 | $1,688 | $21 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 24 | $1,472 | $32 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 29 | $1,387 | $32 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 19 | $1,323 | $22 |
| Injection, zoledronic acid, 1 mg | 23 | $1,289 | None |
| Administration of additional new drug or substance into vein using push technique | 14 | $1,283 | $61 |
| Injection of drug or substance into vein | 22 | $1,107 | $48 |
| Irrigation of implanted venous access drug delivery device | 22 | $792 | $28 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 13 | $734 | $35 |
| Collection of blood sample from implanted device | 15 | $592 | $25 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 18 | $433 | $22 |
| Injection, dexamethasone sodium phosphate, 1 mg | 44 | $78 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 34 | $41 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 31 | $24 | None |
2017: 40 services
| Injection, rituximab, 100 mg | 13 | $93,123 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 23 | $74,937 | None |
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 17 | $70,503 | None |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 12 | $55,482 | None |
| Return visit (30+ min) | 209 | $43,808 | $93 |
| Administration of chemotherapy into vein, 1 hour or less | 105 | $35,393 | $143 |
| Injection, denosumab, 1 mg | 12 | $35,049 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 16 | $26,511 | None |
| Leuprolide acetate (for depot suspension), 7.5 mg | 23 | $15,639 | None |
| Short return visit (20+ min) | 148 | $10,899 | $59 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 68 | $10,080 | $71 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $8,694 | $93 |
| Injection of additional new drug or substance into vein | 71 | $6,146 | $23 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $4,693 | $77 |
| Administration of additional new drug or substance into vein, 1 hour or less | 32 | $4,510 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 23 | $4,340 | $65 |
| New patient visit (45+ min) | 28 | $4,256 | $152 |
| Injection of drug or substance under skin or into muscle | 60 | $3,780 | $25 |
| Long return visit (40+ min) | 23 | $3,639 | $125 |
| Administration of chemotherapy into vein, each additional hour | 37 | $3,529 | $28 |
| Injection of drug or substance into vein | 47 | $3,312 | $56 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 37 | $2,333 | $31 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 25 | $2,242 | $19 |
| New patient visit (30+ min) | 21 | $1,952 | $93 |
| Administration of additional new drug or substance into vein using push technique | 16 | $1,802 | $64 |
| Injection, zoledronic acid, 1 mg | 36 | $1,728 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 31 | $1,718 | $33 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 11 | $1,082 | None |
| Hospital discharge day management, more than 30 minutes | 11 | $1,080 | $98 |
| Injection, carboplatin, 50 mg | 19 | $885 | None |
| Irrigation of implanted venous access drug delivery device | 22 | $808 | $24 |
| Injection, paclitaxel, 1 mg | 13 | $685 | None |
| Infusion into a vein for hydration, each additional hour | 15 | $678 | $15 |
| Transfusion of blood or blood products | 11 | $482 | $37 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 14 | $281 | $20 |
| Injection, dexamethasone sodium phosphate, 1 mg | 59 | $163 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 44 | $78 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 35 | $45 | None |
| Infusion, normal saline solution, 250 cc | 20 | $44 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 11 | $28 | None |
2016: 32 services
| Return visit (30+ min) | 221 | $41,652 | $87 |
| Injection, bortezomib, 0.1 mg | 11 | $39,413 | None |
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 13 | $39,256 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 16 | $37,703 | None |
| Administration of chemotherapy into vein, 1 hour or less | 82 | $21,275 | $139 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 12 | $20,497 | None |
| Long return visit (40+ min) | 53 | $10,900 | $131 |
| Short return visit (20+ min) | 112 | $9,387 | $58 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 12 | $7,663 | None |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 16 | $5,820 | $77 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 51 | $5,266 | $71 |
| Injection of additional new drug or substance into vein | 62 | $4,109 | $23 |
| Administration of additional new drug or substance into vein, 1 hour or less | 27 | $3,454 | $64 |
| Administration of chemotherapy into vein, each additional hour | 33 | $2,891 | $28 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $2,500 | $93 |
| New patient visit (30+ min) | 25 | $2,354 | $94 |
| Injection, zoledronic acid, 1 mg | 26 | $2,321 | None |
| Injection of drug or substance into vein | 22 | $2,080 | $56 |
| Injection of drug or substance under skin or into muscle | 43 | $1,774 | $24 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 22 | $1,367 | $18 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $965 | $64 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 23 | $919 | $31 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 18 | $683 | $33 |
| Irrigation of implanted venous access drug delivery device | 19 | $643 | $26 |
| Injection, carboplatin, 50 mg | 16 | $581 | None |
| Injection, paclitaxel, 1 mg | 12 | $569 | None |
| Infusion into a vein for hydration, each additional hour | 11 | $384 | $15 |
| Injection, dexamethasone sodium phosphate, 1 mg | 50 | $105 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 35 | $57 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 30 | $25 | None |
| Infusion, normal saline solution, 250 cc | 18 | $21 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 11 | $17 | None |
2015: 40 services
| Injection, rituximab, 100 mg | 17 | $110,642 | None |
| Injection, bevacizumab, 10 mg | 11 | $95,805 | None |
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 11 | $46,379 | None |
| Return visit (30+ min) | 214 | $44,112 | $98 |
| Administration of chemotherapy into vein, 1 hour or less | 85 | $35,298 | $145 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 13 | $17,126 | None |
| Short return visit (20+ min) | 157 | $12,157 | $62 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 14 | $11,368 | None |
| Injection, tbo-filgrastim, 5 micrograms | 19 | $10,914 | None |
| Injection of additional new drug or substance into vein | 70 | $8,572 | $24 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 62 | $8,250 | $75 |
| Unclassified drugs | 11 | $8,016 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 26 | $7,904 | $98 |
| Long return visit (40+ min) | 38 | $7,849 | $140 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 13 | $7,155 | $80 |
| Administration of additional new drug or substance into vein, 1 hour or less | 40 | $5,856 | $67 |
| Injection, zoledronic acid, 1 mg | 23 | $4,347 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 22 | $3,255 | $68 |
| Injection of drug or substance under skin or into muscle | 54 | $3,210 | $26 |
| New patient visit (30+ min) | 29 | $2,986 | $103 |
| Injection of drug or substance into vein | 21 | $2,693 | $61 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 21 | $2,559 | $19 |
| Administration of chemotherapy into vein, each additional hour | 34 | $2,456 | $30 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 22 | $1,339 | $32 |
| Hospital discharge day management, more than 30 minutes | 12 | $1,331 | $102 |
| Injection, paclitaxel, 1 mg | 20 | $1,260 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 26 | $1,136 | $34 |
| Injection, carboplatin, 50 mg | 22 | $1,015 | None |
| New patient visit (15+ min) | 14 | $980 | $70 |
| Infusion into a vein for hydration, 31-60 minutes | 12 | $805 | $62 |
| Irrigation of implanted venous access drug delivery device | 19 | $653 | $26 |
| Collection of blood sample from implanted device | 11 | $571 | $25 |
| Short return visit | 13 | $530 | $41 |
| Infusion into a vein for hydration, each additional hour | 14 | $402 | $16 |
| Injection, dexamethasone sodium phosphate, 1 mg | 56 | $178 | None |
| Injection, hydrocortisone sodium succinate, up to 100 mg | 12 | $85 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 50 | $69 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 43 | $45 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 11 | $37 | None |
| Infusion, normal saline solution, 250 cc | 16 | $17 | None |
2014: 26 services
| Injection, rituximab, 100 mg | 13 | $109,957 | None |
| Return visit (30+ min) | 190 | $41,585 | $95 |
| Administration of chemotherapy into vein, 1 hour or less | 83 | $29,443 | $136 |
| Short return visit (20+ min) | 133 | $11,237 | $62 |
| Injection of additional new drug or substance into vein | 74 | $7,500 | $22 |
| Administration of additional new drug or substance into vein, 1 hour or less | 47 | $7,399 | $63 |
| Injection, zoledronic acid, 1 mg | 14 | $6,975 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $5,360 | $92 |
| Long return visit (40+ min) | 30 | $4,934 | $133 |
| New patient visit (45+ min) | 27 | $3,983 | $148 |
| New patient visit (30+ min) | 33 | $3,310 | $100 |
| Administration of chemotherapy into vein, each additional hour | 40 | $2,764 | $28 |
| Injection of drug or substance under skin or into muscle | 39 | $2,615 | $25 |
| Administration of additional new drug or substance into vein using push technique | 20 | $2,304 | $62 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 34 | $1,832 | $30 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 16 | $1,823 | $70 |
| Injection, carboplatin, 50 mg | 29 | $1,561 | None |
| New patient visit (15+ min) | 21 | $1,398 | $67 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $961 | $64 |
| Injection, paclitaxel, 30 mg | 14 | $914 | None |
| Infusion into a vein for hydration, each additional hour | 11 | $448 | $15 |
| Administration of influenza virus vaccine | 12 | $365 | $30 |
| Irrigation of implanted venous access drug delivery device | 11 | $331 | $21 |
| Injection, dexamethasone sodium phosphate, 1 mg | 69 | $183 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 57 | $89 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 34 | $39 | None |
2013: 22 services
| Return visit (30+ min) | 168 | $37,665 | $96 |
| Administration of chemotherapy into vein, 1 hour or less | 58 | $17,962 | $144 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 11 | $9,025 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $7,252 | $90 |
| Short return visit (20+ min) | 90 | $7,086 | $60 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 39 | $4,408 | $76 |
| Administration of additional new drug or substance into vein, 1 hour or less | 28 | $4,143 | $73 |
| Injection of additional new drug or substance into vein | 49 | $2,951 | $23 |
| New patient visit (30+ min) | 29 | $2,856 | $98 |
| Long return visit (40+ min) | 19 | $2,784 | $133 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 32 | $2,564 | $32 |
| New patient visit (45+ min) | 13 | $1,962 | $151 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $1,809 | $62 |
| Injection of drug or substance under skin or into muscle | 34 | $1,601 | $26 |
| Administration of chemotherapy into vein, each additional hour | 20 | $1,534 | $31 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 17 | $1,200 | $21 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 11 | $1,128 | None |
| Injection, carboplatin, 50 mg | 17 | $532 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 40 | $100 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 48 | $92 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 16 | $15 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 11 | $15 | None |
Medicaid work
$124 in 2024
Medicaid paid $124 for 40 billed services this clinician did in 2024, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Infusion, normal saline solution, 250 cc | 40 | $124 |
| 2024 | 40 | 1 | 12 | $124 |
Drugs they prescribed that Part D paid
$1,707,429
Pharmacies billed $1,707,429 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 3% of their Part D prescriptions (26 of 1,015) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%.
856 generic and fewer than 11 brand-name prescriptions · $1,707,429 in drug cost · 40 antibiotic prescriptions to 22 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Tagrisso | 21 | $327,524 | $15,596 |
| Verzenio | 12 | $204,276 | $17,023 |
| Revlimid | 14 | $165,145 | $11,796 |
| Gilotrif | 12 | $136,830 | $11,403 |
| Anastrozole | 213 | $4,889 | $23 |
See all 18 drugs
| Tagrisso | 21 | $327,524 | $15,596 |
| Verzenio | 12 | $204,276 | $17,023 |
| Revlimid | 14 | $165,145 | $11,796 |
| Gilotrif | 12 | $136,830 | $11,403 |
| Anastrozole | 213 | $4,889 | $23 |
| Exemestane | 17 | $4,163 | $245 |
| Letrozole | 73 | $2,202 | $30 |
| Tamoxifen Citrate | 72 | $1,851 | $26 |
| Alendronate | 115 | $1,324 | $12 |
| Oxycodone-Acetaminophen | 13 | $812 | $62 |
| Dexamethasone | 20 | $476 | $24 |
| Prochlorperazine Maleate | 31 | $450 | $15 |
| Prednisone | 47 | $372 | $8 |
| Levothyroxine | 23 | $321 | $14 |
| Acyclovir | 13 | $248 | $19 |
| Ondansetron | 16 | $117 | $7 |
| Lorazepam | 11 | $96 | $9 |
| Sulfamethoxazole-Trimethoprim | 11 | $54 | $5 |
Year by year
| 2024 | 1,015 | 215 | 3% (26) | None | $1,707,429 |
| 2023 | 972 | 204 | 7% (64) | None | $1,119,864 |
| 2022 | 816 | 187 | 8% (62) | None | $1,714,963 |
| 2021 | 878 | 170 | 5% (47) | 15% | $1,523,122 |
| 2020 | 813 | 157 | 5% (38) | None | $1,127,182 |
| 2019 | 998 | 183 | 8% (75) | None | $1,338,292 |
| 2018 | 894 | 163 | 8% (72) | 14% | $909,195 |
| 2017 | 939 | 155 | 9% (84) | 11% | $607,262 |
| 2016 | 1,141 | 169 | 10% (114) | 16% | $872,546 |
| 2015 | 936 | 164 | 11% (98) | None | $572,261 |
| 2014 | 851 | 157 | 11% (92) | 11% | $213,655 |
| 2013 | 709 | 133 | 13% (90) | 8% | $127,767 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 22 drugs
| Tagrisso | 24 | $454,919 | $18,955 |
| Revlimid | 15 | $247,669 | $16,511 |
| Anastrozole | 177 | $5,689 | $32 |
| Letrozole | 68 | $5,089 | $75 |
| Exemestane | 12 | $4,470 | $373 |
| Tamoxifen Citrate | 61 | $2,140 | $35 |
| Alendronate | 101 | $1,462 | $14 |
| Prochlorperazine Maleate | 42 | $848 | $20 |
| Dexamethasone | 30 | $646 | $22 |
| Mirtazapine | 19 | $538 | $28 |
| Ondansetron | 29 | $437 | $15 |
| Acyclovir | 14 | $383 | $27 |
| Levothyroxine | 18 | $340 | $19 |
| Hydrocodone-Acetaminophen | 16 | $301 | $19 |
| Oxycodone-Acetaminophen | 19 | $265 | $14 |
| Prednisone | 40 | $245 | $6 |
| Ciprofloxacin | 13 | $195 | $15 |
| Zolpidem | 15 | $143 | $10 |
| Acetaminophen-Codeine | 12 | $138 | $11 |
| Methadone | 11 | $126 | $11 |
| Lorazepam | 12 | $81 | $7 |
| Sertraline | 11 | $77 | $7 |
2022: 19 drugs
| Xtandi | 29 | $393,266 | $13,561 |
| Revlimid | 18 | $304,651 | $16,925 |
| Tagrisso | 14 | $251,380 | $17,956 |
| Eliquis | 15 | $7,958 | $531 |
| Imatinib Mesylate | 11 | $7,188 | $653 |
| Anastrozole | 139 | $4,119 | $30 |
| Letrozole | 58 | $3,585 | $62 |
| Tamoxifen Citrate | 63 | $2,962 | $47 |
| Alendronate | 74 | $1,005 | $14 |
| Dexamethasone | 25 | $800 | $32 |
| Hydrocodone-Acetaminophen | 22 | $713 | $32 |
| Ondansetron | 25 | $606 | $24 |
| Prochlorperazine Maleate | 30 | $601 | $20 |
| Oxycodone-Acetaminophen | 18 | $440 | $24 |
| Zolpidem | 15 | $264 | $18 |
| Acetaminophen-Codeine | 14 | $260 | $19 |
| Hydroxyurea | 12 | $187 | $16 |
| Ciprofloxacin | 12 | $178 | $15 |
| Prednisone | 11 | $102 | $9 |
2021: 21 drugs
| Tagrisso | 18 | $366,139 | $20,341 |
| Imbruvica | 17 | $236,814 | $13,930 |
| Xtandi | 16 | $208,731 | $13,046 |
| Revlimid | 12 | $196,210 | $16,351 |
| Eliquis | 26 | $12,847 | $494 |
| Tamoxifen Citrate | 73 | $5,569 | $76 |
| Anastrozole | 122 | $4,479 | $37 |
| Letrozole | 54 | $3,538 | $66 |
| Prochlorperazine Maleate | 43 | $1,073 | $25 |
| Alendronate | 72 | $871 | $12 |
| Dexamethasone | 24 | $674 | $28 |
| Ondansetron | 24 | $642 | $27 |
| Mirtazapine | 28 | $335 | $12 |
| Prednisone | 44 | $313 | $7 |
| Sertraline | 17 | $301 | $18 |
| Hydrocodone-Acetaminophen | 11 | $265 | $24 |
| Zolpidem | 15 | $264 | $18 |
| Lorazepam | 13 | $244 | $19 |
| Acyclovir | 15 | $227 | $15 |
| Ciprofloxacin | 13 | $154 | $12 |
| Acetaminophen-Codeine | 12 | $132 | $11 |
2020: 18 drugs
| Tagrisso | 24 | $565,935 | $23,581 |
| Abiraterone Acetate | 12 | $8,605 | $717 |
| Eliquis | 16 | $8,362 | $523 |
| Tamoxifen Citrate | 62 | $5,839 | $94 |
| Anastrozole | 123 | $4,486 | $36 |
| Letrozole | 47 | $2,323 | $49 |
| Prochlorperazine Maleate | 30 | $791 | $26 |
| Alendronate | 54 | $689 | $13 |
| Hydrocodone-Acetaminophen | 12 | $519 | $43 |
| Mirtazapine | 26 | $503 | $19 |
| Dexamethasone | 16 | $394 | $25 |
| Lactulose | 18 | $371 | $21 |
| Prednisone | 45 | $342 | $8 |
| Acyclovir | 22 | $303 | $14 |
| Zolpidem | 12 | $249 | $21 |
| Ondansetron | 14 | $231 | $17 |
| Methadone | 13 | $156 | $12 |
| Lorazepam | 13 | $104 | $8 |
2019: 23 drugs
| Tagrisso | 27 | $506,112 | $18,745 |
| Abiraterone Acetate | 19 | $57,511 | $3,027 |
| Eliquis | 29 | $16,381 | $565 |
| Tamoxifen Citrate | 71 | $5,202 | $73 |
| Exemestane | 11 | $4,501 | $409 |
| Anastrozole | 126 | $3,842 | $30 |
| Letrozole | 51 | $1,522 | $30 |
| Hydrocodone-Acetaminophen | 40 | $1,208 | $30 |
| Prochlorperazine Maleate | 54 | $834 | $15 |
| Prednisone | 64 | $726 | $11 |
| Alendronate | 35 | $490 | $14 |
| Morphine Sulfate Er | 11 | $412 | $37 |
| Gabapentin | 23 | $352 | $15 |
| Ondansetron | 29 | $330 | $11 |
| Acyclovir | 21 | $289 | $14 |
| Dexamethasone | 13 | $274 | $21 |
| Zolpidem | 15 | $234 | $16 |
| Lactulose | 12 | $213 | $18 |
| Lidocaine Hcl Viscous | 15 | $208 | $14 |
| Ciprofloxacin | 13 | $144 | $11 |
| Mirtazapine | 23 | $125 | $5 |
| Sulfamethoxazole-Trimethoprim | 12 | $71 | $6 |
| Lorazepam | 13 | $67 | $5 |
2018: 21 drugs
| Tagrisso | 27 | $398,364 | $14,754 |
| Revlimid | 13 | $234,128 | $18,010 |
| Exemestane | 27 | $16,040 | $594 |
| Tamoxifen Citrate | 112 | $9,120 | $81 |
| Anastrozole | 91 | $2,193 | $24 |
| Morphine Sulfate Er | 27 | $1,332 | $49 |
| Letrozole | 48 | $1,303 | $27 |
| Hydrocodone-Acetaminophen | 22 | $1,061 | $48 |
| Prochlorperazine Maleate | 46 | $600 | $13 |
| Gabapentin | 19 | $568 | $30 |
| Omeprazole | 13 | $493 | $38 |
| Alendronate | 39 | $469 | $12 |
| Prednisone | 30 | $323 | $11 |
| Mirtazapine | 23 | $314 | $14 |
| Dexamethasone | 11 | $284 | $26 |
| Lorazepam | 35 | $207 | $6 |
| Ciprofloxacin | 11 | $202 | $18 |
| Ondansetron | 16 | $174 | $11 |
| Acyclovir | 17 | $160 | $9 |
| Lidocaine Hcl Viscous | 12 | $92 | $8 |
| Azithromycin | 13 | $81 | $6 |
2017: 25 drugs
| Revlimid | 12 | $205,907 | $17,159 |
| Tarceva | 19 | $143,035 | $7,528 |
| Exemestane | 31 | $18,873 | $609 |
| Tamoxifen Citrate | 128 | $8,253 | $64 |
| Eliquis | 15 | $8,026 | $535 |
| Letrozole | 56 | $2,817 | $50 |
| Anastrozole | 101 | $2,229 | $22 |
| Morphine Sulfate Er | 20 | $1,306 | $65 |
| Duloxetine | 12 | $861 | $72 |
| Hydrocodone-Acetaminophen | 40 | $817 | $20 |
| Gabapentin | 25 | $589 | $24 |
| Acyclovir | 19 | $581 | $31 |
| Bicalutamide | 19 | $470 | $25 |
| Alendronate | 37 | $424 | $11 |
| Dexamethasone | 21 | $396 | $19 |
| Mirtazapine | 22 | $328 | $15 |
| Prednisone | 37 | $325 | $9 |
| Omeprazole | 14 | $198 | $14 |
| Warfarin | 12 | $174 | $14 |
| Methadone | 12 | $164 | $14 |
| Ondansetron | 13 | $126 | $10 |
| Lorazepam | 23 | $125 | $5 |
| Prochlorperazine Maleate | 15 | $117 | $8 |
| Ciprofloxacin | 14 | $106 | $8 |
| Azithromycin | 13 | $75 | $6 |
2016: 26 drugs
| Tarceva | 58 | $373,454 | $6,439 |
| Xtandi | 14 | $128,007 | $9,143 |
| Exemestane | 53 | $20,779 | $392 |
| Tamoxifen Citrate | 99 | $4,126 | $42 |
| Letrozole | 83 | $3,640 | $44 |
| Anastrozole | 96 | $2,528 | $26 |
| Hydrocodone-Acetaminophen | 34 | $1,292 | $38 |
| Morphine Sulfate Er | 32 | $1,036 | $32 |
| Zolpidem | 24 | $676 | $28 |
| Gabapentin | 23 | $617 | $27 |
| Diphenoxylate-Atropine | 13 | $575 | $44 |
| Ondansetron | 28 | $401 | $14 |
| Prednisone | 36 | $400 | $11 |
| Alendronate | 31 | $389 | $13 |
| Dexamethasone | 32 | $382 | $12 |
| Prochlorperazine Maleate | 35 | $352 | $10 |
| Mirtazapine | 17 | $286 | $17 |
| Clonidine | 12 | $242 | $20 |
| Ciprofloxacin | 14 | $206 | $15 |
| Sodium Chloride | 16 | $198 | $12 |
| Omeprazole | 11 | $178 | $16 |
| Acetaminophen-Codeine | 11 | $172 | $16 |
| Azithromycin | 17 | $170 | $10 |
| Atenolol | 16 | $158 | $10 |
| Lorazepam | 33 | $152 | $5 |
| Finasteride | 12 | $84 | $7 |
2015: 19 drugs
| Tarceva | 31 | $208,937 | $6,740 |
| Zytiga | 17 | $134,235 | $7,896 |
| Imbruvica | 11 | $102,999 | $9,364 |
| Exemestane | 68 | $25,152 | $370 |
| Tamoxifen Citrate | 78 | $3,620 | $46 |
| Morphine Sulfate Er | 37 | $3,555 | $96 |
| Anastrozole | 93 | $2,351 | $25 |
| Letrozole | 86 | $2,228 | $26 |
| Zolpidem | 27 | $751 | $28 |
| Hydrocodone-Acetaminophen | 23 | $514 | $22 |
| Ondansetron | 20 | $316 | $16 |
| Alendronate | 25 | $267 | $11 |
| Prochlorperazine Maleate | 32 | $241 | $8 |
| Mirtazapine | 20 | $237 | $12 |
| Prednisone | 23 | $223 | $10 |
| Omeprazole | 13 | $195 | $15 |
| Lorazepam | 29 | $158 | $5 |
| Dexamethasone | 14 | $157 | $11 |
| Citalopram Hbr | 14 | $96 | $7 |
2014: 18 drugs
| Zytiga | 15 | $100,177 | $6,678 |
| Exemestane | 27 | $14,551 | $539 |
| Morphine Sulfate Er | 41 | $3,000 | $73 |
| Anastrozole | 78 | $2,991 | $38 |
| Tamoxifen Citrate | 56 | $2,338 | $42 |
| Letrozole | 73 | $1,475 | $20 |
| Gabapentin | 21 | $493 | $23 |
| Prednisone | 49 | $486 | $10 |
| Levothyroxine | 15 | $416 | $28 |
| Prochlorperazine Maleate | 31 | $352 | $11 |
| Zolpidem | 30 | $331 | $11 |
| Ondansetron | 16 | $272 | $17 |
| Dexamethasone | 25 | $269 | $11 |
| Mirtazapine | 14 | $265 | $19 |
| Hydrocodone-Acetaminophen | 13 | $260 | $20 |
| Lorazepam | 34 | $226 | $7 |
| Alendronate | 14 | $180 | $13 |
| Clonidine | 12 | $66 | $6 |
2013: 19 drugs
| Anastrozole | 92 | $4,798 | $52 |
| Morphine Sulfate Er | 35 | $1,761 | $50 |
| Letrozole | 46 | $1,753 | $38 |
| Bicalutamide | 19 | $1,706 | $90 |
| Tamoxifen Citrate | 49 | $1,338 | $27 |
| Gabapentin | 30 | $844 | $28 |
| Ondansetron | 18 | $677 | $38 |
| Prochlorperazine Maleate | 34 | $441 | $13 |
| Alendronate | 20 | $406 | $20 |
| Mirtazapine | 17 | $267 | $16 |
| Citalopram Hbr | 16 | $236 | $15 |
| Dexamethasone | 25 | $234 | $9 |
| Omeprazole | 16 | $233 | $15 |
| Zolpidem | 16 | $213 | $13 |
| Warfarin | 14 | $209 | $15 |
| Ciprofloxacin | 14 | $167 | $12 |
| Lorazepam | 22 | $161 | $7 |
| Hydrocodone-Acetaminophen | 13 | $122 | $9 |
| Prednisone | 16 | $120 | $8 |
Money from drug and device companies
$279 in 2025
| 2025 | 10 | 11 | None | $279 |
| 2024 | 1 | 1 | None | $31 |
| 2022 | 1 | 1 | None | $32 |
| 2021 | 1 | 1 | None | $13 |
| 2019 | 1 | 1 | None | $12 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Merck Sharp & Dohme | Keytruda | $63 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $32 | 1 payment
|
| Genentech USA | Gazyva | $30 | 1 payment
|
| Abbvie | Venclexta | $29 | 1 payment
|
| Incyte | Jakafi | $27 | 1 payment
|
| Array Biopharma | Lorbrena | $25 | 1 payment
|
See all 11 published payments
| Genentech USA | Meals · 2025-12-17 | Gazyva | $30 |
| Incyte | Meals · 2025-11-13 | Jakafi | $27 |
| Daiichi Sankyo | Meals · 2025-11-06 | Datroway | $19 |
| GlaxoSmithKline | Meals · 2025-11-04 | Blenrep | $21 |
| Merck Sharp & Dohme | Meals · 2025-10-08 | Keytruda | $33 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-09-24 | Opdivo | $32 |
| Genmab U.S. | Meals · 2025-09-22 | Epkinly | $18 |
| Abbvie | Meals · 2025-09-10 | Venclexta | $29 |
| Array Biopharma | Meals · 2025-07-09 | Lorbrena | $25 |
| Pfizer | Education · 2025-04-28 | Ibrance | $16 |
| Merck Sharp & Dohme | Meals · 2025-04-15 | Keytruda | $30 |
See earlier years (2024, 2022, 2021, 2019)
2024: $31
| Eisai | Leqembi | $31 | 1 payment
|
2022: $32
| Pfizer | Ibrance | $32 | 1 payment
|
2021: $13
| Pfizer | Inlyta | $13 | 1 payment
|
2019: $12
| Seattle Genetics | Adcetris | $12 | 1 payment
|
Professional record
- NPI
- 1114034832
- Licence
- CA A63128California A63128: Current · expires 2026-10-31
- Trained
- Yale University School of Medicine, 1996
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 2350 W El Camino Real, 2nd Floor, Mountain View, CA, 94040
- NPI first listed
- 2006-08-25
- NPI last updated
- 2017-02-27
This is when the NPI record was last certified, not a medical board exam.